scholarly journals Patients with checkpoint inhibitor‐induced inflammatory arthritis do not become seropositive for anti‐cyclic citrullinated peptide when followed over time

2021 ◽  
Author(s):  
Laura C. Cappelli ◽  
Erika Darrah ◽  
Ami A. Shah ◽  
Clifton O. Bingham
Keyword(s):  
Inflammatory Arthritis ◽  
Checkpoint Inhibitor ◽  
Cyclic Citrullinated Peptide ◽  
Citrullinated Peptide ◽  
Over Time

The prevalence of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis

2005 ◽  
Vol 0 (0) ◽  
Author(s):  
Sandra H. Machado ◽  
Carlos A. von Mühlen ◽  
João C. T. Brenol ◽  
Letícia Bisotto ◽  
Ricardo Machado Xavier
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Cyclic Citrullinated Peptide ◽  
Citrullinated Peptide ◽  
Peptide Antibodies

Citrulline-independent positivity of anti cyclic citrullinated peptide antibodiES (ANTI-CCP) in type 1 autoimmune hepatitis (AIH-1)

2006 ◽  
Vol 38 (9) ◽  
pp. A83-A84
Author(s):  
A. Vannini ◽  
A.J.W. Zendman ◽  
A.C. Dall’Aglio ◽  
G. Ballardini ◽  
D. Zauli ◽  
...  
Keyword(s):  
Autoimmune Hepatitis ◽  
Cyclic Citrullinated Peptide ◽  
Citrullinated Peptide ◽  
Peptide Antibodies

scholarly journals AB0224 ASSOCIATIONS BETWEEN JOINT REPLACEMENT HISTORY AND CYCLIC CITRULLINATED PEPTIDE ANTIBODY TITERS IN RHEUMATOID ARTHRITIS PATIENTS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1412.2-1412
Author(s):  
M. Sato ◽  
M. Takemura
Keyword(s):  
Rheumatoid Arthritis ◽  
Joint Replacement ◽  
Disease Duration ◽  
Certolizumab Pegol ◽  
Biologic Agent ◽  
Cyclic Citrullinated Peptide ◽  
Replacement Procedure ◽  
Antibody Titers ◽  
Age Range ◽  
Citrullinated Peptide

Background:High titers of cyclic citrullinated peptide antibodies (anti-CCP) are predictive of poor prognosis in the treatment of rheumatoid arthritis (RA). The 2010 ACR/EULAR classification criteria for early RA assign a high point value to cases having highly positive anti-CCP titers. Previous reports have claimed that osteoarthritic damage is more severe and advanced in RA patients who test positive for anti-CCP than in their negative counterparts.Objectives:To retrospectively investigate whether anti-CCP titers were associated with the extent of osteoarthritic damage in RA patients treated at our institution.Methods:Data were analyzed for 422 RA patients who received biologic agents due to resistance to methotrexate or other conventional antirheumatic drugs. Associations were explored between joint replacement history-i.e. total knee replacement (TKR), total hip replacement (THR), or lack thereof—and anti-CCP positivity rates and titers.Results:The sample consisted of 90 men and 332 women. On average, patients were put on biologics at 58.6 years of age (range: 22–85), and had a disease duration of 9.3 years. The first biologic agent chosen was infliximab (IFX) in 154 cases, etanercept (ETN) in 76, adalimumab (ADA) in 61, tocilizumab (TCZ) in 70, abatacept (ABT) in 41, golimumab (GLM) in 18, and certolizumab pegol (CZP) in 2. In total, 331/422 patients (78.4%) tested positive for anti-CCP. TKR was performed in 46 cases (M:F ratio: 7:39, mean age: 64.7 y, mean disease duration: 15.1 y), of which 46 were positive for anti-CCP (100%). THR was performed in 18 cases (M:F ratio: 2:16, mean age: 62.3 y, mean disease duration: 18.5 y), of which 17 were positive for anti-CCP (94.4%). The mean anti-CCP titer among all positive patients (n=331) was 152.9 IU/ml. This value was significantly higher in patients who underwent either joint replacement procedure than those who did not (215.4 v. 142.8 IU/ml, p<0.0005).Conclusion:With one exception, all RA patients who underwent joint replacement were positive for anti-CCP, and their titers were higher than non-surgical cases. Practitioners should be aware of this trend, and pay attention to the progression of damage in the knee and hip joints when treating RA patients with high anti-CCP titers.Disclosure of Interests:None declared

A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis

2008 ◽  
Vol 28 (2) ◽  
pp. 153-158 ◽  
Author(s):  
Lisiane Maria Enriconi dos Anjos ◽  
Ivanio Alves Pereira ◽  
Eleonora d ‘Orsi ◽  
Andrea Piette Seaman ◽  
Rufus Watson Burlingame ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Comparative Study ◽  
Third Generation ◽  
Cyclic Citrullinated Peptide ◽  
Citrullinated Peptide
Sign in / Sign up

Export Citation Format

Share Document